

Eur. J. Biochem. 259, 555–564 (1999) © FEBS 1999

REVIEW ARTICLE

Protein kinase C δ

Michael Gschwendt

German Cancer Research Center, Heidelberg, Germany

The protein kinase C (PKC) family consists of 11 isoenzymes that, due to structural and enzymatic differences, can be subdivided into three groups: The Ca^{2+} -dependent, diacylglycerol (DAG)-activated cPKCs (conventional PKCs: α , β_1 , β_2 , γ); the Ca^{2+} -independent, DAG-activated nPKCs (novel PKCs: δ , ϵ , η , θ , μ), and the Ca^{2+} -dependent, DAG non-responsive aPKCs (atypical PKCs: ζ , λ). PKC μ is a novel PKC, but with some special structural and enzymatic properties.

Keywords: protein kinase C δ ; activation; autophosphorylation; down-regulation; structure; tyrosine phosphorylation; function.

Protein kinase C δ (PKC δ) is the most thoroughly studied member of the nPKC subfamily. After the discovery of the enzyme in 1986, its cloning in 1987, and its first purification to homogeneity in 1990, several groups have focused their interest on this PKC isoenzyme and have reported on its expression, structural and enzymatic properties, and cellular functions. Some information has accumulated on the mode and structural requirements of activation and down-regulation of PKC δ . Recently, the role of phosphorylation of PKC δ , i.e. either autophosphorylation or phosphorylation by an exogenous protein kinase, for the regulation of its enzymatic activity could to some extent be elucidated and compared to that of other PKC isoforms. However, many questions remain to be answered. The same holds true for PKC δ -specific substrate phosphorylation and biological functions. Various more or less useful methods have been applied to elucidate PKC δ -specific functions in a given cell. Data accumulated that indicate a role of PKC δ in growth inhibition, differentiation, apoptosis, and tumor suppression. However, the knowledge on PKC δ -specific substrate phosphorylation resulting in these specific cellular effects is as yet extremely poor.

The PKC family

Protein kinase C (PKC) was initially identified and characterized as a proteolytically activated kinase called protein kinase M [1,2]. The proenzyme (PKC) was then shown to exhibit calcium- and phospholipid-dependent kinase activity independently of proteolytic activation [3]. In the presence of diacylglycerol (DAG), a well-known second messenger molecule [4,5], the calcium concentration necessary for stimulation of the enzyme was reduced to physiological levels [6]. DAG was known to be produced by phosphatidylinositol turnover induced by cellular

receptors upon interaction with numerous extracellular factors [4,5]. This indicated that PKC might play an important role in transmembrane signal transduction. Another key discovery was that PKC was the major intracellular receptor for the tumor-promoting phorbol esters, such as 12-*O*-tetradecanoylphorbol 13-acetate (TPA) [7,8]. When TPA was used as PKC activator *in vivo*, PKC proved to be linked to the signal-induced modulation of a wide variety of cellular processes, such as growth, differentiation, secretion, apoptosis, and tumor development. In 1986, the cDNAs of three PKC isoenzymes (α , β , γ) were cloned [9–11]. The PKC β gene was found to generate two isoforms, β_1 and β_2 , by alternative splicing [12].

Since then, seven other isoenzymes [δ , ϵ , η , θ , ζ , λ (ι), μ] and PKC-related kinases (PRKs) have been detected (for reviews on PKC isoenzymes see [13–16]). The PKC family can be subdivided into three groups. The 'conventional' PKCs (cPKCs; α , β_1 , β_2 , γ) depend on calcium and are activated by diacylglycerol (DAG) or TPA; the 'novel' PKCs (nPKCs; δ , ϵ , η , θ) are also activated by DAG or TPA but are calcium-independent; the 'atypical' PKCs (aPKCs; ζ , λ (ι)) are calcium-independent and do not respond to DAG or TPA. The difference between the three subfamilies is reflected by differences in the molecular structures. The cysteine-rich sequences of cPKCs and nPKCs have been shown to be the site of interaction with phospholipid and diglyceride/phorbol ester activators [17]. The aPKCs lack one cysteine-rich sequence and are not activated by diglycerides or phorbol esters. However, a phorbol ester-responsive aPKC ζ can be generated by fusion with the regulatory domain of PKC δ [18]. nPKCs lack the C2 region that determines Ca^{2+} -binding by the cPKC subfamily. PKC μ is a novel PKC but contains a pleckstrin homology domain and a N-terminal hydrophobic domain and it lacks a region resembling the inhibitory pseudosubstrate regions of other PKC family members. Protein kinase C isoenzymes are activated by a very large number of extracellular signals and in turn modify the activities of a wide variety of cellular proteins including receptors, enzymes, cytoskeletal proteins, transcription factors, etc. Thus, PKC has a central position in cellular signal processing.

Cell-specific expression and subcellular localization of individual PKC isoenzymes indicate important isoenzyme-specific functions. To elucidate such functions, it will be necessary to study *in vitro* and/or *in vivo* the individual features of each isoenzyme, such as expression, post-translational modification, substrate specificity, subcellular localization and

Correspondence to: M. Gschwendt, German Cancer Research Center, Room H530, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. Tel.: +49 6221424505, Fax: +49 6221424554.

E-mail: m.gschwendt@dkfz-heidelberg.de

Abbreviations: PKC, protein kinase C; DAG, diacylglycerol; TPA, 12-*O*-tetradecanoylphorbol 13-acetate; Cys, cysteine-rich motif; eEF-1 α , eucaryotic elongation factor-1 α ; HSP, heat shock protein; RACK, receptor for activated C-kinase; AKAP, anchoring protein for cAMP-dependent protein kinase.

(Received 1 September 1998, revised 30 October 1998, accepted 13 November 1998)

© FEBS 1999

556 M. Gschwendt (*Eur. J. Biochem.* 259)

signaling cross-talk with other proteins. In addition, the involvement of a PKC isoenzyme in a signaling pathway resulting in a specific cellular response can be investigated by several distinct methods such as overexpression of the enzyme or inhibition of enzyme expression or activity. The purpose of this article is to review our present knowledge regarding the PKC δ , a member of the nPKC subfamily, that attracted the interest of an increasing number of research groups over the last years.

Structure of PKC δ

In 1987, i.e. 1 year after cloning of the cPKCs (α , β , γ), a cDNA of PKC δ was cloned from a rat brain cDNA library by Ono *et al.* [19]. The PKC δ gene could be assigned to human chromosome 3 and mouse chromosome 14 [20]. The amino acid sequence of PKC δ showed 58% homology to PKC α [21]. As a member of the nPKC subfamily, PKC δ contains a carboxy-terminal catalytic domain with two conserved regions, C3 and C4, essential for catalytic activity and substrate binding, and an amino-terminal regulatory domain with an inhibitory pseudo-substrate sequence and two cysteine-rich Zn-finger-like sequences in the C1 region but lacking the C2 region. The cysteine-rich motifs of PKC δ are functionally not equivalent. Glutathione-S-transferase fusion proteins containing the second cysteine-rich motif (Cys2) of PKC δ bind the phorbol ester PDBu with high affinity, whereas no significant binding is seen for the Cys1 fusion proteins [22]. Mutational studies indicate that Cys2 plays a key role in the translocation of cytosolic PKC δ to cellular membranes in response to an activation by phorbol ester [23]. Site-directed mutagenesis [24] and X-ray crystallographic studies [25] provided detailed understanding of the interaction between phorbol ester and Cys2 of PKC δ . Five of six cysteine residues as well as the two histidine residues involved in Zn²⁺ coordination were found to be critical for phorbol ester binding. In addition, mutations in other positions of Cys2 drastically reduce the interaction with the ligand. In a groove at the tip of Cys2 the oxygens at the C-3, C-4, and C-20 position of the phorbol moiety are thought to form hydrogen bonds with main-chain groups the orientation of which is controlled by a set of highly conserved residues. Phorbol ester binding caps the groove and forms a contiguous hydrophobic surface, explaining how the activator promotes insertion of PKC δ into membranes.

Purification and characterization of PKC δ

PKC δ was the first nPKC isoenzyme to be isolated from a tissue. In 1986, we reported on the isolation of a phorbol ester/phospholipid-activated, Ca²⁺-unresponsive PKC-like enzyme [26–28], which later on was identified as PKC δ . The native enzyme was purified to homogeneity from porcine spleen and characterized [29]. It bound the phorbol ester TPA with high affinity ($K_d = 9.6$ nM) and could be activated *in vitro* for substrate and autophosphorylation by TPA (or diacylglycerol) plus phosphatidyl serine, but unlike the cPKCs (α , β , γ), not by calcium plus phosphatidyl serine. Activation was brought about also with various unsaturated fatty acids, particularly arachidonic acid. The affinity of native PKC δ for cofactors and substrates differed to some extent from that of conventional PKCs. In the meantime, both native and recombinant PKC δ have been partially or completely purified also from various other sources, such as rat brain [30], mouse hemopoietic cells [31], COS1 cells transfected with cDNA coding for rat [32] or mouse [33] PKC δ , and insect cells infected with recombinant baculovirus containing the cDNA of human PKC δ [34] as well

as bacteria transfected with rat PKC δ cDNA [35]. The properties of the various PKC δ preparations did not differ significantly.

PKC δ has been found in most tissues and cell types [36,37]. The expression of the enzyme is ontogenetically regulated. Thus, the concentration of PKC δ in the epidermis and brain of newborn mice increases dramatically between day 7 and 14 after birth [36]. A detailed immunohistochemical investigation of the expression of PKC δ and other PKC isoforms in rat cerebellum was carried out by Chen and Hillman [38,39]. They observed a transient occurrence of PKC δ in glia and later its appearance in selective groups of neurons. The expression of PKC δ was associated with specific activities of these cells.

Like other isoenzymes of the cPKC and nPKC groups, PKC δ is activated *in vivo* by DAG that is formed from phospholipids upon receptor-mediated activation of phospholipases [40]. While numerous signaling molecules, such as growth factors, hormones and cytokines, are known to cause DAG release and activation of PKC, reports on a selective activation of individual PKC isoenzymes are rare. The nPKCs δ and ϵ , but not the cPKCs, were found to be activated upon mitogenic stimulation of quiescent rat 3Y1 fibroblasts [41]. A selective activation of PKC δ may play a role in nerve growth factor-induced neurite outgrowth [42]. Cis-unsaturated fatty acids activate PKC *in vitro* and in intact platelets. According to Khan *et al.* [43], oleate activates mainly PKC δ . In none of these cases the mechanism of the apparently selective activation of PKC δ is known yet.

Similarly to other PKC isoforms, PKC δ is proteolytically degraded following activation by TPA *in vivo*. Physiological agonists causing DAG release, such as bombesin and PDGF, and DAG itself, are also able to cause degradation of PKC δ [40]. This so-called down-regulation occurs via the ubiquitin-proteasome pathway [44]. TPA treatment of mouse skin causes down-regulation of epidermal PKC δ with a half-life of around 8 h, followed by complete recovery within 72 h [36]. According to a report by Shih and Floyd-Smith [45], TPA induces down-regulation of PKC δ in the mouse B lymphoma cell line A20 not only at the protein but also at the mRNA level. Down-regulation of PKC δ in Swiss 3T3 cells appears to be cell-cycle-dependent, operating only in the G0/G1 [46]. Paradoxically, the PKC activator bryostatin 1 protects PKC δ , but not other PKC isoforms, against TPA-induced down-regulation in mouse keratinocytes [47]. Protection is observed at 100 nM to 1 μ M, whereas at concentrations of less than 1 nM, bryostatin 1 itself causes down-regulation of PKC δ to a similar extent as does TPA. Studies with reciprocal chimeras constructed by exchanging the regulatory and catalytic domains of PKC α and PKC δ grants that the catalytic domain of PKC δ confers protection by bryostatin 1 against down-regulation and contains the isotype-specific determinants involved in the unique effect of bryostatin 1 on PKC δ [48].

Recently, various PKC-specific inhibitors have been identified or developed (for a review see [49]). Among these, rottlerin was found to possess some specificity for PKC δ [50]. However, no absolutely PKC δ -specific inhibitor is available as yet. The staurosporine-related compound K252a and the staurosporine-derived compound Gö 6976 are able to differentiate between subgroups of PKC [28,51,52] in that these inhibit Ca²⁺-responsive isoforms much more effectively than Ca²⁺-unresponsive isoforms including PKC δ .

Expression of PKC δ

Contrary to PKC β and γ , the PKC δ gene has not been cloned yet. Thus, the regulatory regions of the gene and respective factors that might affect the onset of transcription are not

BEST AVAILABLE COPY

Protein kinase C δ (Eur. J. Biochem. 259) 557

© FEBS 1999




Fig. 1. Phosphorylation and activation of PKC β II and PKC δ . PKC β II is synthesized as a catalytically incompetent enzyme that requires phosphorylation by the PKC kinase (PDK1) of threonine 500 (T500) in the activation loop for catalytic competence. Subsequent (auto)phosphorylation of threonine 641 (T641) and serine 660 (S660) is necessary for maintaining a catalytically competent conformation and the regulation of subcellular distribution [69]. It is not yet absolutely clear whether both sites (T641 and S660) are autophosphorylated or another kinase is involved. The stable catalytically-competent form of PKC β II can be activated by Ca^{2+} , phospholipid (PL) and diacylglycerol (DAG) for substrate phosphorylation. PKC δ is synthesized as a catalytically competent enzyme that is activated by PL and DAG for autophosphorylation and substrate phosphorylation. Phosphorylation of T505 (corresponding to T500 of PKC β II) is not required for catalytic competence [35]. The negative charge in the activation loop that is necessary for catalytic competence of PKC δ is probably provided by glutamic acid 500 (E500) [67]. PKC δ is autophosphorylated *in vitro* on serine 643 (S643; [67]). Probably, additional (auto)phosphorylation sites exist, but have not been identified. The role of PKC δ (auto)phosphorylation is not yet clear.

known. However, up- and down-regulation of the expression of PKC δ in various cells and tissues was reported and evidence for an isotype-specific expression was obtained. Thus, estrogen treatment increases the level of PKC δ protein in rabbit [53] and rat corpora lutea [54], probably by a post-transcriptional mechanism, whereas the levels of other PKC isoforms remain relatively constant. Interleukin-1 β induces the expression of PKC δ and ϵ , but not of α and ζ , in NIH 3T3 cells [55]. 1,25-Dihydroxyvitamin D $_3$ stimulates the expression of PKC δ and α in acute promyelocytic NB4 cells via a nongenomic mechanism [56]. The authors propose that by increasing the expression of these PKC isoforms the cells are primed for TPA-induced monocyte differentiation. Assert *et al.* [57] reported on a 400% increase of PKC δ -mRNA in human T84 cells 24 h after TPA treatment. However, the level of PKC δ protein was not elevated to the same degree as that of mRNA. Elevated PKC δ - (and ϵ) mRNA levels were reported to occur also upon treatment of α T3-1 cells with gonadotropin-releasing hormone. This process appeared to be autoregulated by PKC [58]. Cross-talk between

PKC isoenzymes also might regulate PKC levels. Overexpression of PKC α in Baf3 and 32D cells leads to an elevation of the endogenous PKC δ protein level, altering its mRNA transcription and degradation [59]. Stable transfection of the human keratinocyte line HaCaT with mutated cellular Ha-ras results in a selective loss of PKC δ -mRNA and protein that is mediated by TGF α [60]. This is in accordance with a proposed tumor-suppressive role of PKC δ .

Phosphorylation of PKC δ

Phosphorylation in the activation loop by a 'PKC kinase'? PKC δ seems to differ from other PKC isoenzymes in its mechanism of post-translational regulation. PKC α [61] and β II [62] are known to require phosphorylation of threonine 497 and 500, respectively, in the so-called activation loop for enzymatic activity. Very recently, the 'PKC kinase' responsible for this phosphorylation has been found to be the phosphoinositide-dependent kinase PDK1 [63–65]. This kinase is most likely not

present in bacteria. This would explain that PKC α could not be expressed as an active recombinant enzyme in bacteria [66]. Gschwendt and coworkers showed that PKC δ , contrary to PKC α , can be expressed in a catalytically competent form in bacteria [35]. Recombinant PKC δ partially purified from bacteria had a specific activity comparable to that of native PKC δ from porcine spleen. In addition, it was demonstrated by site-directed mutagenesis that phosphorylation of threonine 505 in PKC δ , unlike that of the corresponding threonines in PKC α and β , is not essential for a permissive activation of PKC δ (see Fig. 1). The negative charge in the activation loop of PKC δ that is necessary for catalytic competence of the kinase is probably provided by glutamic acid 500. Mutation of this acidic amino acid residue to valine caused an 80% loss of kinase activity [67]; see Fig. 1). These results do not exclude modulation of PKC δ activity due to phosphorylation by another kinase, but they indicate that PKC δ and other PKC isoenzymes are differentially regulated by post-translational modification.

Autophosphorylation. Like many other protein kinases, PKC isoenzymes undergo autophosphorylation the functional role of which is still a matter of debate. PKC δ purified to homogeneity from porcine spleen exhibits a particularly high potential for autophosphorylation *in vitro*, which is around four times that of the cPKCs α , β , γ . The stoichiometry and phosphoamino acid analysis of autophosphorylation *in vitro* suggested that fully phosphorylated PKC δ contains two phosphoserine residues and one phosphothreonine [29]. *In vitro* PKC δ accepts not only ATP but also GTP as phosphate donor for autophosphorylation [68].

While PKC β was found to be autophosphorylated *in vivo* on threonine 641 and serine 660 [69,70], the *in-vivo* (auto)phosphorylation sites of PKC δ have not been unequivocally identified yet. Recently, site-directed mutagenesis of serine 643 and comparison of *in-vivo* phosphorylated wild-type and alanine mutant by phosphopeptide mapping indicated that serine 643 is an *in-vivo* phosphorylation site of PKC δ [71]. Phosphorylation of this site appeared to be important for enzymatic activity. These data did not indicate whether serine 643 is autophosphorylated or phosphorylated by another protein kinase. Stempka *et al.* [67] identified serine 643 as an *in-vitro* autophosphorylation site of PKC δ by MALDI mass spectrometry of tryptic peptides derived from recombinant PKC δ that was purified from bacteria or baculovirus-infected insect cells. In contrast to the report by Li *et al.* [71], Stempka *et al.* [67] were unable to demonstrate any loss of kinase activity upon serine 643 to alanine mutation. Thus, the role of PKC δ autophosphorylation is not yet clear, particularly, as probably additional, as yet unidentified (auto)phosphorylation sites exist (see Fig. 1).

Phosphorylation of tyrosine residues. PKC δ was the first PKC isoenzyme found to be functionally modulated by tyrosine phosphorylation. The tyrosine kinase Src phosphorylates PKC δ *in vitro* [72]. *In-vitro* tyrosine phosphorylation occurs only in the presence of an activator, i.e. TPA, and thus appears to be restricted to the activated form of the enzyme. Possibly, the phosphorylation sites are exposed only upon an activator-induced conformational change of PKC δ . Tyrosine phosphorylation increases the apparent molecular mass of PKC δ and modifies its activity towards some substrates. Tyrosine phosphorylation of PKC δ was demonstrated also *in vivo* in response to treatment of cells with various agents, such as TPA, PDGF, TGF α , carbachol, substance P, ligand of IgE receptor, extracellular ATP or UTP, and H₂O₂ [73–79], and in response to transfection of murine keratinocytes with oncogenic Ha-ras [80].

Upon treatment of PKC δ -overexpressing cells with PDGF or TPA, tyrosine-phosphorylated PKC δ was found to be localized

in the membrane fraction and its activity increased [74]. According to Konishi *et al.* [78] and Kadowaki *et al.* [81], tyrosine phosphorylation of PKC δ *in vivo* creates a modified enzyme that is active without or at least with a lower concentration of lipid cofactors. Upon treatment of cells with H₂O₂, not only PKC δ but also PKC α , β , γ , ϵ , and ζ were found to be tyrosine-phosphorylated and activated [78]. In contrast to these studies, tyrosine phosphorylation was reported to diminish the activity of PKC δ [75,77,80]. According to *in vitro* studies [72], it seems to depend on the substrate whether PKC activity is elevated or reduced by tyrosine phosphorylation. In other words, tyrosine phosphorylation might regulate the specificity of the kinase toward a given substrate. For example, PKC δ that was phosphorylated on tyrosine upon activation of the high-affinity receptor for IgE has diminished activity toward the γ -chain peptide of this receptor as a substrate but not toward histones or myelin basic protein peptide [77]. It is not known yet whether PKC δ is phosphorylated *in vivo*, as *in vitro*, by Src or another tyrosine kinase. However, it was shown that PKC δ associates with v-Src and is phosphorylated on tyrosine and activated in v-Src-transformed fibroblasts [82,83]. Very recently, association with Src and tyrosine phosphorylation of PKC δ was observed also in MCF-7 human breast cancer cells in the absence of overexpression of either PKC δ or Src [84]. Moreover, various mitogenic agents, including the phorbol ester TPA, activate Src-family kinases in Swiss 3T3 cells [85], epidermal keratinocytes [75], or MCF-7 cells [84]. Even though activation of the EGF receptor results in tyrosine phosphorylation of PKC δ , the EGF receptor tyrosine kinase is not able to phosphorylate PKC δ *in vitro* [72]. Thus, it is very well conceivable that the EGF receptor signal is mediated by Src. Recently, the c-Abl tyrosine kinase was found to be associated with PKC δ in diverse cell types, such as MCF-7 cells, U-937 cells, and HL-60 myeloid leukemia cells [86]. Treatment of those cells with DNA-damaging agents is associated with c-Abl-dependent phosphorylation of PKC δ and translocation of PKC δ to the nucleus. c-Abl phosphorylates and activates PKC δ also *in vitro*. These data suggest that, possibly in addition to Src, Abl is a PKC δ tyrosine kinase *in vivo*.

Site-directed mutagenesis indicated that tyrosine 52 [87], tyrosine 187 [88], tyrosine 512 and 523 [78] are all sites for tyrosine phosphorylation of PKC δ *in vivo*. However, these sites have not been identified unequivocally yet, for example by MALDI mass spectrometry of tryptic peptides of tyrosine-phosphorylated PKC δ .

Biological functions of PKC δ

Various methods have been applied to elucidate PKC δ functions. Differential down-regulation of PKC isoenzymes by TPA, bryostatin, etc., can be used to selectively remove from or retain PKC δ in a cell. A TPA-induced physiological response in such cells or its lack is then attributed to the action of PKC δ . This method was applied to show that PKC δ is involved in the stimulation of the Na⁺–H⁺ exchanger in C₆ glioma cells [89], in phosphoinositide hydrolysis and PGE₂ formation [90], and in keratinocyte differentiation [47]. Similarly, it was demonstrated that selective activation of PKC δ might play a role in neuritogenic signals in PC12 cells [42]. Even if selectivity and duration of down-regulation have been carefully checked, this method is of limited use only. The effects of TPA are manifold and therefore, one cannot exclude the possibility that the observed cellular response or its lack is the consequence of a TPA effect other than down-regulation of PKC. Alternatively, PKC δ can be inhibited by expression of a dominant negative

© FEBS 1999

Protein kinase C δ (*Eur. J. Biochem.* 259) 559

ATP-binding mutant of the enzyme [91] or its expression can be suppressed by treatment of cells with antisense oligonucleotides to PKC δ . These methods are much more specific than TPA-induced down-regulation. The use of a dominant negative mutant indicated that PKC δ is involved in *Sis*-induced transformation of NIH 3T3 cells via the activation of genes containing the TPA responsive element, but not via the Ras cascade [92]. Antisense oligonucleotides were used to demonstrate a role of PKC δ in differentiation of murine erythroleukemia cells [93] and in the α_1 -adrenergic activation of Na⁺-K⁺-2Cl cotransport [94].

A method frequently used for studying PKC δ function is the establishment of stable cell clones that overexpress PKC δ upon transfection with corresponding expression vectors. Changes in cellular processes, observed with and/or without treatment of the transfected cells with TPA, are then regarded to be mediated by PKC δ . However, overexpression is not necessarily physiologically relevant. For example, the overexpressed PKC isoenzyme may overwhelm the endogenous enzyme and thus cause nonspecific localization and substrate phosphorylation. Several groups reported that overexpression of PKC δ causes growth inhibition, as for instance in CHO cells [95], in smooth muscle cells [96], in NIH 3T3 fibroblasts [97], in human glioma cells [98], and in capillary endothelial cells [99]. In these studies, additional effects of PKC δ overexpression were reported, such as changes in cell morphology, decreased cell density, and suppression of G₁ cyclin expression. In some reports changes were accentuated by treatment of cells with the phorbol ester TPA. Overexpression of PKC δ (and α), but not β_1 , ϵ , η , or ζ , enables the murine myeloid 32D cells to differentiate into mature macrophages after treatment with TPA [100] or PDGF [101]. Using overexpression of reciprocal δ and ϵ chimeras, it was shown that the catalytic domain of PKC δ mediates the TPA-induced differentiation of 32D cells [102]. Overexpression of PKC δ in NIH 3T3 cells increases the sodium-dependent phosphate uptake [103]. By application of this method it was shown also that PKC δ , but not β_1 , ϵ , or ζ , inhibits the activation of the STAT signaling pathway by the Tec-family kinase Bmx [104]. Moreover, it was demonstrated that PKC δ (and PKC α) mediates the transcription of TPA-inducible genes via both AP-1 and non-AP-1 sequences [105]. Ras-dependent signal transduction is involved in the activation of AP-1 by PKC δ [106]. Contrary to that, PKC δ activates the MEK-ERK pathway independently of Ras and dependently of Raf, as was demonstrated by expression of a constitutively active mutant of PKC δ [107]. Alternatively to transfection of cells with a PKC δ cDNA and overexpression of PKC δ , the enzyme can be directly introduced into permeabilized cells. By applying this method it was demonstrated that PKC δ is involved in exocytosis [108].

Besides the involvement of PKC δ in the regulation of cell growth and differentiation, this PKC isoform might play a role also in apoptosis and tumor development. Emoto *et al.* [109–111] demonstrated that apoptosis induced in human myeloid leukemia cells by TNF α , ara-C, and Fas-antibody, radiation, etc. was associated with proteolytic activation of PKC δ by an ICE-like protease. It was shown that the cysteine protease CPP32 is responsible for this cleavage. The proteolytic generation of a 40-kDa catalytic kinase fragment (aa 331–676) upon induction of apoptosis can be suppressed by overexpression of the anti-apoptotic proteins Bcl-2 and Bcl-x_L. Overexpression of the catalytic kinase fragment of PKC δ , but not of full-length PKC δ or a kinase-inactive fragment, caused phenotypic changes associated with apoptosis. Similar results were reported by Mizuno *et al.* [112]. However, the authors

demonstrated apoptosis-associated limited proteolytic cleavage not only of PKC δ but also of other nPKC isotypes, such as PKC ϵ and θ , whereas PKC α , β , and ζ were not affected. Ceramide-induced cytosolic translocation of PKC δ and ϵ was observed in HL60 cells and may be a prerequisite for the proteolytic activation of the kinases in apoptosis [113]. Very recently, Bharti *et al.* [114] reported on an interaction of the catalytic fragment of PKC δ with and phosphorylation of the DNA-dependent protein kinase (DNA-PK) resulting in the inactivation of this kinase. DNA-PK is essential in the repair of DNA double-strand breaks. Thus, interaction of PKC δ and DNA-PK may contribute to DNA damage-induced apoptosis.

The possible role of PKC δ in the induction of apoptosis may be at least one reason for its tumor-suppressive action that has been indicated by several reports. Overexpression of PKC δ in the liver particulate fraction of low protein-fed rats correlates with inhibition of the development of preneoplastic lesions in diethylnitrosamine-induced rat hepatocarcinogenesis [115]. Expression of PKC δ in human keratinocytes is significantly reduced upon ras transformation [60]. Induction of a transformed phenotype by TPA in c-Src overexpressing rat fibroblasts appears to be due to depletion, and not activation, of PKC δ [116], since it could be evoked by expression of a dominant negative PKC δ mutant as well as treatment with the PKC δ inhibitor rottlerin. Moreover, bryostatin 1, which inhibits TPA-induced down-regulation of PKC δ specifically [47], blocks TPA-induced tumor promotion in mouse skin [117]. TPA-induced tyrosine phosphorylation of PKC δ , for instance by Src, might be a signal for its proteolytic degradation (Gschwendt *et al.*, unpublished results) eliminating protection against tumor development. Indeed, v-Src was shown to be associated with and down-regulate PKC δ [83]. Very recently, Reddig *et al.* [118] demonstrated that transgenic mice overexpressing PKC δ in the epidermis showed a dramatic reduction in the formation of skin tumors upon treatment with 7,12-dimethylbenz[*a*]anthracene/TPA.

Substrates and binding proteins

One of the most important tasks in learning to understand the function of individual PKC isoenzymes is the search for physiological substrates and associating proteins. A large number of proteins are known that are phosphorylated by PKC. However, the knowledge of proteins that are selectively phosphorylated by a distinct PKC isoform is extremely scarce. Essentially two mechanisms are conceivable that may enable a PKC isoenzyme, like PKC δ , to phosphorylate a substrate protein selectively and thus transduce an isoenzyme-specific signal. A PKC isoenzyme might recognize a consensus sequence of a substrate protein that is not or just poorly recognized by the other isoenzymes. Alternatively or in addition, colocalization of a PKC isoenzyme with substrates in a cell compartment might determine the specificity of substrate phosphorylation.

An example for a substrate protein with a specific recognition site for PKC δ is the eucaryotic elongation factor-1 α (eEF-1 α), which is phosphorylated at threonine 431 selectively by PKC δ [119]. Moreover, the eEF-1 α peptide 422–443 containing the phosphorylation site is an absolutely specific substrate for the δ -type of PKC. A single basic amino acid close to the phosphorylation site is essential for specific recognition and phosphorylation of the peptide by PKC δ . Substitution of this basic amino acid by alanine abolishes the ability of PKC δ to phosphorylate the peptide, and insertion of additional basic amino acids in the vicinity of the phosphorylation site causes a complete loss of selectivity. Phosphorylation and activation of

eEF-1 in intact cells upon treatment with TPA was reported previously [120,121].

As another PKC δ -specific substrate the γ -chain of the high-affinity receptor for immunoglobulin E that is associated with PKC δ has been described [122]. The γ -chain is phosphorylated *in vivo* on a threonine residue in response to PKC activation. The phosphorylation correlates with the endocytosis of the receptor. However, the phosphorylation site has not been identified and the essential amino acid(s) for specific recognition by PKC δ are not known yet. Jideama *et al.* [123] reported on a PKC δ -specific phosphorylation site in troponin I. PKC δ was found to be unique among all PKC isoenzymes in its ability to mimic protein kinase A in phosphorylating Ser 23/Ser 24 of this protein and in reducing Ca^{2+} sensitivity of Ca^{2+} -stimulated MgATPase of reconstituted actomyosin S-1. In addition PKC δ , like PKC α , phosphorylates Ser-43/Ser-45 and reduces maximal activity of MgATPase. Most of the *in-vitro* phosphorylation sites were confirmed *in situ* in adult rat cardiomyocytes. The heat-shock protein-25/27 (HSP-25/27) was shown to be efficiently phosphorylated by PKC δ and to a lesser extent by PKC α , whereas other PKC isoforms (β_1 , β_2 , ϵ , ζ) were not effective HSP kinases [124]. A physiological significance of this phosphorylation was indicated by the finding that HSP-27 was more strongly phosphorylated *in vivo* in rat corpora lutea of late pregnancy, a developmental stage in which PKC δ is abundant and active. Moreover, late-pregnancy luteal extracts contain a lipid-sensitive HSP-kinase activity which is copurified with PKC δ .

Isoenzyme-specific binding proteins and scaffolding or anchoring proteins, such as RACKs, AKAPs, etc. [125], which are able to bind the isoenzyme and the substrates, most likely play an essential role in colocalizing kinase and substrate.

Little is known about the localization of PKC δ in or translocation to cell compartments that might determine selectivity of substrate phosphorylation. Taken together, data are accumulating that indicate an association of PKC δ with nuclear and cytoskeletal structures of the cell. In most cases, however, a link to selective phosphorylation of substrate proteins by PKC δ is missing. Lebersperger *et al.* [36] reported on a nuclear or perinuclear localization of PKC δ in skin sections. Similar results have been obtained for bovine brain cells [126]. In cultured cells of neuronal origin, PKC δ was found in nucleoli [127]. A redistribution of PKC δ from a peri-nuclear/cytoplasmic compartment to a putatively cytoskeletal location upon activation of a human T cell line was reported by Keenan *et al.* [128]. A TPA-induced association of PKC δ with the cytoskeleton was also found in beta cells. Oleic acid inhibits translocation to the cytoskeleton and rather induces an association with membranes, indicating that different activators of PKC δ may have different effects on the localization of the enzyme within the cell [129]. In HL60 cells, PKC δ was found to colocalize with the PKC substrate vimentin in the cytosol and perinuclear region [130]. Barry & Crichtley [131] demonstrated that in Swiss 3T3 cells serum induced the recruitment of PKC δ together with focal adhesion kinase (pp125FAK) to newly formed focal adhesions.

Almost nothing is known about proteins that bind specifically PKC δ and might be important for intracellular targeting of this PKC isoform. Receptors for activated C-kinases (RACKs) specific for PKC β_{II} and PKC ϵ were described. Moreover, the existence of receptors for inactive C-kinase (RICKs), with characteristics similar to the anchoring proteins for cAMP-dependent protein kinase (AKAPs), has been discussed (for a review see [125]). PKC δ -specific RACKs or RICKs are not known yet. However, data reported by Jakou and coworkers

indicate that the regulatory domain of PKC δ and other PKC isoenzymes is involved in the interaction with other proteins [132,133]. Indeed, a binding site of PKC δ for a putatively specific RACK was found to be localized in the N-terminal V1 domain (amino acids 1–142). This domain resembles to some extent the C2 domain of cPKCs, which is known to interact with RACKs. A peptide corresponding to this PKC δ domain selectively prevented translocation of PKC δ upon cell stimulation [134]. Similarly, binding of the PKC substrate GAP-43 to this domain of PKC δ was reported [135]. Some other proteins, such as MARCKS [136] and SRBC [137] are not only phosphorylated by PKC δ and other PKC isoenzymes but also bind to the regulatory domain of PKC δ with a rather high affinity ($K_m = 20$ –60 nM). Therefore, a PKC receptor function of these proteins has been discussed. An isoenzyme-specific interaction of PKC δ with phosphatidylinositol 3-kinase was detected by coimmunoprecipitation [138]. The association is modulated by cell activation. Its function is not yet known.

Conclusion

Within the last decade, after the discovery of PKC δ in 1986 and its cloning in 1987, quite a number of data have accumulated. The native enzyme as well as recombinant enzymes were purified and characterized. Particularly the role of the second cysteine-rich motif in binding the activating phorbol esters was studied in detail. Beside the activation by cofactors, that is distinct with cPKCs, nPKCs, and aPKCs, most properties of PKC δ known so far do not differ significantly from those of all other PKC isoenzymes. The selective protection by bryostatin 1 from TPA-induced down-regulation, the lacking requirement for threonine phosphorylation in the activation loop for permissive activation of the enzyme, and possibly tyrosine phosphorylation as a response to extracellular stimuli were all found to be special characteristics of PKC δ . Tyrosine phosphorylation as a response to extracellular stimuli, however, might occur also with other PKC isoforms, as indicated by a recent report. Several studies suggested PKC δ to be involved in the regulation of cell growth and differentiation and to play a role in apoptosis and tumor development. However, the signaling pathways leading to these cellular processes, particularly the role of PKC δ in this signaling, is not or just poorly understood. A major drawback is the missing knowledge of physiological substrates and PKC δ associated proteins determining the specific functions of this PKC isoenzyme in a cell. Therefore, one of the most important tasks in future studies on PKC δ will be the search for proteins, including substrate proteins, that specifically interact with PKC δ . Presently, methods like the yeast two-hybrid system or overlay techniques are applied for this purpose.

ACKNOWLEDGEMENTS

I thank Friedrich Marks for critical reading of the manuscript before its submission. Research in the author's laboratory is supported by the Deutsche Forschungsgemeinschaft and the Wilhelm Sander-Stiftung.

REFERENCES

1. Inoue, M., Kishimoto, A., Takai, Y. & Nishizuka, Y. (1977) Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues: proenzyme and its activation by calcium-dependent protease from rat brain. *J. Biol. Chem.* **252**, 7610–7616.
2. Takai, Y., Kishimoto, A., Inoue, M. & Nishizuka, Y. (1977) Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues: purification and characterization

© FEBS 1999

Protein kinase C δ (*Eur. J. Biochem.* 259) 561

- of an active enzyme from bovine cerebellum. *J. Biol. Chem.* 252, 7603–7609.
3. Takai, Y., Kishimoto, A., Iwasa, Y., Kawahara, Y., Mori, T. & Nishizuka, Y. (1979) Calcium-dependent activation of a multi-functional protein kinase by membrane phospholipids. *J. Biol. Chem.* 254, 3692–3695.
 4. Mitchell, R.H. (1975) Inositol phospholipids and cell surface receptor function. *Biochim. Biophys. Acta* 415, 81–147.
 5. Berridge, M.J. (1984) Inositol trisphosphate and diacylglycerol as second messengers. *Biochem. J.* 220, 345–360.
 6. Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U. & Nishizuka, Y. (1980) Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. *J. Biol. Chem.* 255, 2273–2276.
 7. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U. & Nishizuka, Y. (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. *J. Biol. Chem.* 257, 7847–7851.
 8. Nield, J.E., Kuhn, L.J. & Vandenberg, G.R. (1983) Phorbol diester receptor copurifies with protein kinase C. *Proc. Natl Acad. Sci. USA* 80, 36–40.
 9. Coonsens, L., Parker, P.J., Rhoe, L., Yang-Feng, T.L., Chen, E., Waterfield, M.D., Francke, U. & Ullrich, A. (1986) Multiple, distinct forms of bovine and human protein kinase C, suggests diversity in cellular signaling pathways. *Science* 233, 859–866.
 10. Parker, P., Coonsens, L. & Tony, N. (1986) The complete primary structure of PKC- the major phorbol ester receptor. *Science* 233, 853–859.
 11. Knopf, J., Lee, M.-H. & Sultzman, L.A. (1986) Cloning and expression of multiple protein kinase C cDNAs. *Cell* 46, 491–502.
 12. Ono, Y. & Nishizuka, Y. (1986) Cloning of rat brain PKC cDNA. *FEBS Lett.* 203, 111–115.
 13. Mellor, H. & Parker, P.J. (1998) The extended protein kinase C superfamily. *Biochem. J.* 332, 281–292.
 14. Parker, P.J. & Dekker, L.V. (ed.) (1997) *Protein Kinase C*. Springer, London.
 15. Marks, F. & Gschwendt, M. (1996) Protein Kinase C. In *Protein Phosphorylation* (Marks, F., ed.), pp. 81–116. VCH, Weinheim.
 16. Blobe, G.C., Stibbing, S., Oseld, L.M. & Hannon, Y.A. (1996) Protein kinase C isoenzymes: regulation and function. *Cancer Surveys* 27, 213–248.
 17. Ono, Y., Fujii, T., Igarashi, K., Kuno, T., Tanaka, C., Kikkawa, U. & Nishizuka, Y. (1989) Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. *Proc. Natl Acad. Sci. USA* 86, 4868–4871.
 18. Goode, N.T. & Parker, P.J. (1994) A phorbol ester-responsive PKC- ζ generated by fusion with the regulatory domain of PKC- δ . *FEBS Lett.* 340, 145–150.
 19. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K. & Nishizuka, Y. (1987) Identification of three additional members of rat protein kinase C family: δ -, ϵ -, and ζ -subspecies. *FEBS Lett.* 226, 125–128.
 20. Huppi, K., Stewski, D., Goodnight, J. & Mischak, H. (1994) Assignment of the protein kinase C δ polypeptide gene (PRKCD) to human chromosome 3 and mouse chromosome 14. *Genomics* 19, 161–162.
 21. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K. & Nishizuka, Y. (1988) The structure, expression, and properties of additional members of the protein kinase C family. *J. Biol. Chem.* 263, 6927–6932.
 22. Hunn, M. & Quest, A.F.G. (1997) Cysteine-rich regions of protein kinase C δ are functionally non-equivalent. Differences between cysteine-rich regions of non-calcium-dependent protein kinase C δ and calcium-dependent protein kinase C γ . *FEBS Lett.* 400, 226–232.
 23. Stallasi, Z., Bogi, K., Gohari, S., Biro, T., Act, P. & Blumberg, P.M. (1996) Non-equivalent roles of the first and second zinc fingers of protein kinase C δ . *J. Biol. Chem.* 271, 18299–18301.
 24. Kazanietz, M.G., Wang, S., Milne, G.W.A., Lewin, N.E., Liu, H.L. & Blumberg, P.M. (1995) Residues in the second cysteine-rich region of protein kinase C δ relevant to phorbol ester binding as revealed by site-directed mutagenesis. *J. Biol. Chem.* 270, 21852–21859.
 25. Zhang, G., Kazanietz, M.G., Blumberg, P.M. & Hurley, J.H. (1995) Crystal structure of the Cys2 activator-binding domain of protein kinase C δ in complex with phorbol ester. *Cell* 81, 917–924.
 26. Gschwendt, M., Kitzstein, W. & Marks, F. (1986) A novel type of phorbol ester-dependent protein phosphorylation in the particulate fraction of mouse epidermis. *Biochem. Biophys. Res. Commun.* 137, 766–774.
 27. Gschwendt, M., Kitzstein, W., Horn, F., Lebersperger, H. & Marks, F. (1989) A phorbol ester and phospholipid-activated, calcium-unresponsive protein kinase in mouse epidermis: characterization and separation from protein kinase C. *J. Cell. Biochem.* 40, 293–307.
 28. Gschwendt, M., Lebersperger, H. & Marks, F. (1989) Differentiative action of K252a on protein kinase C and a calcium-unresponsive, phorbol ester/phospholipid-activated protein kinase. *Biochem. Biophys. Res. Commun.* 164, 974–982.
 29. Lebersperger, H., Gschwendt, M. & Marks, F. (1990) Purification and characterization of a calcium-unresponsive, phorbol ester/phospholipid-activated protein kinase from porcine spleen. *J. Biol. Chem.* 265, 16108–16111.
 30. Ogita, K., Miyamoto, S., Yamaguchi, K., Kolda, H., Fujisawa, N., Kikkawa, U., Sahara, S., Fukami, Y. & Nishizuka, Y. (1992) Isolation and characterization of δ -subspecies of protein kinase C from rat brain. *Proc. Natl Acad. Sci. USA* 89, 1592–1596.
 31. Mischak, H., Bodenteich, A., Kolch, W., Goodnight, J., Hofer, F. & Mushinski, J.F. (1991) Mouse protein kinase C- δ , the major isoform expressed in mouse hematopoietic cells: sequence of the cDNA, expression patterns, and characterization of the protein. *Biochemistry* 30, 7925–7931.
 32. Olivier, A.R. & Parker, P.J. (1991) Expression and characterization of protein kinase C- δ . *Eur. J. Biochem.* 200, 805–810.
 33. Mizuno, M., Kubo, K., Saldo, T.C., Akita, Y., Osada, S., Kuroki, T., Ohno, S. & Suzuki, K. (1991) Structure and properties of a ubiquitously expressed protein kinase C, nPKC δ . *Eur. J. Biochem.* 202, 931–940.
 34. Ania, J.P., Basta, P.V., Holmes, W.D., Ballas, L.M., Moomaw, C., Rankin, N.B., Blobel, G., Loomis, C.R. & Burns, D.J. (1993) Molecular and biochemical characterization of a recombinant human PKC- δ family member. *Biochim. Biophys. Acta* 1174, 171–181.
 35. Stempka, L., Girod, A., Müller, H.J., Rinck, G., Marks, F., Gschwendt, M. & Bossmeyer, D. (1997) Phosphorylation of protein kinase C δ (PKC δ) at threonine 505 is not a prerequisite for enzymatic activity. *J. Biol. Chem.* 272, 6805–6811.
 36. Lebersperger, H., Gschwendt, M., Gernold, M. & Marks, F. (1991) Immunological demonstration of a calcium-unresponsive protein kinase C of the δ -type in different species and murine tissues. *J. Biol. Chem.* 266, 14778–14784.
 37. Wessel, W.C., Khan, W.A., Merchenhauer, I., Rivera, H., Halpern, A.B., Phung, H.M., Nigro-Villar, A. & Hannon, Y.A. (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. *J. Cell Biol.* 117, 121–133.
 38. Chen, S. & Hillman, D.E. (1993) Compartmentation of the cerebellar cortex by protein kinase C δ . *Neuroscience* 56, 177–188.
 39. Chen, S. & Hillman, D.E. (1994) Immunohistochemical localization of protein kinase C δ during postnatal development of the cerebellum. *Develop. Brain Res.* 80, 19–25.
 40. Olivier, A.R. & Parker, P.J. (1994) Bombesin, platelet-derived growth factor, and diacylglycerol induce selective membrane association and down-regulation of protein kinase C isozymes in Swiss 3T3 cells. *J. Biol. Chem.* 269, 2758–2763.
 41. Ohno, S., Mizuno, K., Adachi, Y., Ham, A., Akita, Y., Akimoto, K., Osada, S., Hirai, S. & Suzuki, K. (1994) Activation of novel protein kinase C δ and C ϵ upon mitogenic stimulation of quiescent rat 3Y1 fibroblasts. *J. Biol. Chem.* 269, 17495–17501.
 42. O'Driscoll, K.R., Teng, K.K., Fabbro, D., Greene, L.A. & Weinstein, I.B. (1995) Selective translocation of protein kinase C- δ in PC12 cells during nerve growth factor-induced neurogenesis. *Mol. Biol. Cell* 6, 449–458.

© FEBS 1999

562 M. Gschwendt (Eur. J. Biochem. 259)

43. Khan, W.A., Blobe, G., Halpern, A., Taylor, W., Wexel, W.C., Burns, D., Loomis, C. & Hannun, Y.A. (1993) Selective regulation of protein kinase C isoenzymes by oleic acid in human platelets. *J. Biol. Chem.* **268**, 5063–5068.
44. Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M. & Foster, D.A. (1998) Activation of protein kinase C triggers its ubiquitination and degradation. *Mol. Cell. Biol.* **18**, 839–845.
45. Shih, N.-Y. & Floyd-Smith, G. (1996) Protein kinase C- δ mRNA is down-regulated transcriptionally and post-transcriptionally by 12-O-tetradecanoylphorbol-13-acetate. *J. Biol. Chem.* **271**, 16040–16046.
46. Olivier, A.R., Hansra, G., Pettit, T.R., Wakelam, M.J.O. & Parker, P.J. (1996) The co-mitogenic combination of transforming growth factor β and bombesin protects protein kinase C- δ from late-phase down-regulation, despite synergy in diacylglycerol accumulation. *Biochem. J.* **318**, 519–525.
47. Szallasi, Z., Deming, M.F., Smith, C.B., Dlugosz, A.A., Yuspa, S.H., Pettit, G.R. & Blumberg, P.M. (1994) Bryostatin 1 protects protein kinase C- δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. *Mol. Pharmacol.* **48**, 840–850.
48. Lorenzo, P.S., Bögl, K., Acs, P., Pettit, G.R. & Blumberg, P.M. (1997) The catalytic domain of protein kinase C δ confers protection from down-regulation induced by bryostatin 1. *J. Biol. Chem.* **272**, 33338–33343.
49. Hofmann, J. (1997) The potential for isoenzyme-selective modulation of protein kinase C. *FASEB J.* **11**, 649–669.
50. Gschwendt, M., Müller, H.J., Kielbassa, K., Zang, R., Kiststein, W., Rincke, G. & Marks, F. (1994) Rotlerin, a novel protein kinase inhibitor. *Biochem. Biophys. Res. Commun.* **199**, 93–98.
51. Gschwendt, M., Fürstenberger, G., Leibensperger, H., Kiststein, W., Lindner, D., Rufoloh, C., Barth, H., Kleinschroth, J., Marme, D., Schaehtle, C. & Marks, F. (1995) Lack of an effect of novel inhibitors with high specificity for protein kinase C on the action of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate on mouse skin in vivo. *Carcinogenesis* **16**, 107–111.
52. Martiny-Baron, G., Kazanietz, M.G., Mischak, H., Blumberg, P.M., Kochs, G., Hug, H., Marme, D. & Schaehtle, C. (1993) Selective inhibition of protein kinase C isoenzymes by the indolcarbazole Gö 6976. *J. Biol. Chem.* **268**, 9194–9197.
53. Maizels, E.T., Müller, H.J., Cutler, R.E., Jackiw, V., Carney, R.M., Mizuno, K., Ohno, S. & Hunzicker-Dunn, M. (1992) Estrogen modulates Ca^{2+} -independent lipid-stimulated kinase in the rabbit corpus luteum of pseudopregnancy. *J. Biol. Chem.* **267**, 17061–17068.
54. Cutler, R.E., Maizels, E.T. & Hunzicker-Dunn, M. (1994) δ Protein kinase C in the rat ovary: estrogen regulation and localization. *Endocrinology* **135**, 1669–1678.
55. Varley, C.L., Brown, B.L., Groome, N. & Dobson, P.R.M. (1997) Interleukin-1 β -induced expression of protein kinase C (PKC)- δ and ϵ in NIH 3T3 cells. *Cytokine* **9**, 577–581.
56. Berry, D.M., Antochi, R., Bhalla, M. & Mockling-Gill, K.A. (1996) 1,25-Dihydroxyvitamin D3 stimulates expression and translocation of protein kinase C α and C δ via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells. *J. Biol. Chem.* **271**, 16090–16096.
57. Assert, R., Schatz, H. & Pfeiffer, A. (1996) Upregulation of PKC δ - and downregulation of PKC α -mRNA and protein by a phorbol ester in human T84 cells. *FEBS Lett.* **388**, 195–199.
58. Harris, D., Reiss, N. & Naor, Z. (1997) Differential activation of protein kinase C δ and ϵ gene expression by gonadotropin-releasing hormone in α T3-1 cells. *J. Biol. Chem.* **272**, 13534–13540.
59. Romanova, L.Y., Alexandrov, I.A., Nordan, R.P., Blagosklonny, M.V. & Mushinski, J.F. (1998) Cross-talk between protein kinase C- α (PKC- α) and - δ (PKC- δ): PKC- α elevates the PKC- δ protein level, altering its mRNA transcription and degradation. *Biochemistry* **37**, 5558–5565.
60. Gallego, D., Marks, F. & Gschwendt, M. (1995) Loss of protein kinase C δ from human HaCaT keratinocytes upon Ras transfection is mediated by TGF α . *Exp. Cell Res.* **219**, 299–303.
61. Cozaubon, S., Bormancin, P. & Parker, P.J. (1994) Threonine-497 is a critical site for permissive activation of protein kinase C α . *Biochem. J.* **301**, 443–448.
62. Orr, J.W. & Newton, A.C. (1994) Requirement for negative charge on 'activation loop' of protein kinase C. *J. Biol. Chem.* **269**, 27715–27718.
63. Chou, M.M., Hou, W., Johnson, J., Graham, L.K., Lee, M.H., Chen, C.-S., Newton, A.C., Schaffhausen, B.S. & Toker, A. (1998) Regulation of protein kinase C ζ by PI 3-kinase and PDK1. *Curr. Biol.* **8**, 1069–1077.
64. Ann, Le Good, J., Ziegler, W.H., Parikh, D.B., Alessi, D.R., Cohen, P. & Parker, P.J. (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* **281**, 2042–2045.
65. Dutil, E.M. & Newton, A.C. (1998) Regulation of conventional protein kinase Cs by PDK1. In *ASBMB Symposium on Protein Kinase C and Cellular Function*, Oct. 9–12, 1998, Abstract 95.
66. Filippuzzi, L., Fabbro, D. & Imber, R. (1993) Unphosphorylated alpha-PKC exhibits phorbol ester binding but lacks protein kinase activity in vitro. *J. Cell Biochem.* **52**, 78–83.
67. Stempka, L., Schnölzer, M., Rincke, G., Marks, F. & Gschwendt, M. (1998) In *ASBMB Symposium on Protein Kinase C and Cellular Function*, Oct. 9–12, 1998, Abstract 33.
68. Gschwendt, M., Kiststein, W., Kielbassa, K. & Marks, F. (1995) Protein kinase C δ accepts GTP for autophosphorylation. *Biochem. Biophys. Res. Commun.* **206**, 614–620.
69. Keranen, L.M., Dutil, E.M. & Newton, A.C. (1995) Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. *Curr. Biol.* **5**, 1394–1403.
70. Tanakawa, S.B., Modulbradsky, K.F., Flint, A.J., Burlingame, A.L. & Koshland, D.E. (1995) Determination of in vivo phosphorylation sites in protein kinase C. *J. Biol. Chem.* **270**, 26807–26812.
71. Li, W., Zhang, J., Borzuto, D.P., Li, W. & Pierce, J.H. (1997) Identification of serine 643 of protein kinase C- δ as an important autophosphorylation site for its enzymatic activity. *J. Biol. Chem.* **272**, 24550–24555.
72. Gschwendt, M., Kielbassa, K., Kiststein, W. & Marks, F. (1994) Tyrosine phosphorylation and stimulation of protein kinase C δ from porcine spleen by src in vitro. Dependence on the activated state of protein kinase C δ . *FEBS Lett.* **347**, 85–89.
73. Li, W., Mischak, H., Yu, I.-C., Wang, L.-M., Mushinski, J.F., Heidaran, M.A. & Pierce, J.H. (1994) Tyrosine phosphorylation of protein kinase C- δ in response to its activation. *J. Biol. Chem.* **269**, 2349–2352.
74. Li, W., Yu, J.C., Micheli, P., Fecker, J.F., Ellmore, N., Heidaran, M. & Pierce, J.H. (1994) Stimulation of the platelet-derived growth factor β receptor signaling pathway activates protein kinase C- δ . *Mol. Cell. Biol.* **14**, 6727–6735.
75. Denning, M.F., Dlugosz, A.A., Threadgill, D.W., Magnuson, T. & Yuspa, S.H. (1996) Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C δ . *J. Biol. Chem.* **271**, 5325–5331.
76. Soltoff, S.P. & Toker, A. (1995) Carbachol, substance P, and phorbol ester promote the tyrosine phosphorylation of protein kinase C δ in salivary gland epithelial cells. *J. Biol. Chem.* **270**, 13490–13495.
77. Haleem-Smith, H., Chang, E.-Y., Szallasi, Z., Blumberg, P.M. & Rivera, J. (1995) Tyrosine phosphorylation of protein kinase C- δ in response to the activation of the high-affinity receptor for immunoglobulin E modifies its substrate recognition. *Proc. Natl. Acad. Sci. USA* **92**, 9112–9116.
78. Konishi, H., Tanaka, M., Takemura, Y., Matsuzaki, H., Ono, Y., Kikkawa, U. & Nishizuka, Y. (1997) Activation of protein kinase C by tyrosine phosphorylation in response to H_2O_2 . *Proc. Natl. Acad. Sci. USA* **94**, 11233–11237.
79. Soltoff, S.P., Avraham, H., Avraham, S. & Cantley, L.C. (1998) Activation of Prx receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. *J. Biol. Chem.* **273**, 2633–2650.

© FEBS 1999

Protein kinase C δ (*Eur. J. Biochem.* 259) 563

80. Denning, M.F., Dlugosz, A.A., Howett, M.K. & Yuspa, S.H. (1993) Expression of an oncogenic *ras*^{Ha} gene in murine keratinocytes induces tyrosine phosphorylation and reduced activity of protein kinase C δ . *J. Biol. Chem.* 268, 26079–26081.
81. Kadotani, M., Nishidama, T., Nishihoshi, M., Tsujishita, Y., Ogita, K., Nakamura, S., Kikawa, U. & Asano, Y. (1997) Characterization of tyrosine-phosphorylated δ isoform of protein kinase C isolated from Chinese hamster ovary cells. *J. Biochem.* 121, 1047–1053.
82. Zang, Q., Frankel, P. & Foster, D.A. (1995) Selective activation of protein kinase C isoforms by v-Src. *Cell Growth Diff.* 6, 1367–1373.
83. Zang, Q., Lu, Z., Curio, M., Barile, N., Shalloway, D. & Foster, D.A. (1997) Association between v-Src and protein kinase C δ in v-Src-transformed fibroblasts. *J. Biol. Chem.* 272, 13275–13280.
84. Shanmugam, M., Krett, N.L., Peters, C.A., Maizels, E.T., Mured, P.M., Kawakatsu, H., Rosen, S.T. & Hunzicker-Dunn, M. (1998) Association of PKC δ and active Src in PMA-treated MCF-7 human breast cancer cells. *Oncogene* 16, 1649–1654.
85. Rodríguez-Fernández, J.L. & Rozengurt, E. (1996) Bombesin, bradykinin, vasopressin, and phorbol esters rapidly and transiently activate Src family tyrosine kinases in Swiss 3T3 cells. *J. Biol. Chem.* 271, 27895–27901.
86. Yuan, Z., Utanigawa, T., Ishiko, T., Nakada, S., Huang, Y., Kharbanda, S., Weichselbaum, R. & Kufe, D. (1998) Activation of protein kinase C δ by the c-Abl tyrosine kinase in response to ionizing radiation. *Oncogene* 16, 1643–1648.
87. Szallasi, Z., Denning, M.F., Chang, E.Y., Rivera, J., Yuspa, S.H., Lehel, C., Olah, Z., Anderson, W.B. & Blumberg, P.M. (1995) Development of a rapid approach to identification of tyrosine phosphorylation sites: application to PKC δ phosphorylated upon activation of the high affinity receptor for IgE in rat basophilic leukemia cells. *Biochem. Biophys. Res. Commun.* 214, 888–894.
88. Li, W., Li, W., Chen, X.-H., Kelley, C.A., Alimandi, M., Zhang, J., Chen, Q., Bouvarot, D.P. & Pierce, J.H. (1996) Identification of tyrosine 187 as a protein kinase C- δ phosphorylation site. *J. Biol. Chem.* 271, 26404–26409.
89. Chen, C.-C. & Wu, M.-L. (1995) Protein kinase C isoform δ is involved in the stimulation of the Na⁺-H⁺ exchanger in C₆ glioma cells. *Mol. Pharmacol.* 48, 995–1003.
90. Dwyer, J., Schwende, H., Fitzke, E., Hidve, H. & Diener, P. (1993) Different roles of protein kinase C- β and - δ in arachidonic acid cascade, superoxide formation and phospholipid hydrolysis. *Biochem. J.* 292, 203–207.
91. Li, W., Yu, J.-C., Shin, D.-Y. & Pierce, J.H. (1995) Characterization of a protein kinase C- δ (PKC- δ) ATP binding mutant. *J. Biol. Chem.* 270, 8311–8318.
92. Li, W., Micheli, P., Alimandi, M., Lorenzi, M.V., Wu, Y., Wang, L.-H., Haidara, M.A. & Pierce, J.H. (1996) Expression of an ATP binding mutant of PKC- δ inhibits Src-induced transformation of NIH 3T3 cells. *Oncogene* 13, 731–737.
93. Pessino, A., Passalacqua, M., Sparatore, B., Parron, M., Melloni, E. & Pontremoli, S. (1995) Antisense oligodeoxynucleotide inhibition of δ protein kinase C expression accelerates induced differentiation of murine erythroleukemia cells. *Biochem. J.* 312, 549–554.
94. Liedtke, C.M. & Cole, T. (1997) Antisense oligodeoxynucleotide to PKC- δ blocks α 1-adrenergic activation of Na-K-2Cl cotransport. *Am. J. Physiol.* 273, C1632–C1640.
95. Watanabe, T., Ono, Y., Taniyama, Y., Hazama, K., Igarashi, K., Ogita, K., Kikawa, U. & Nishizuka, Y. (1992) Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C- δ subspecies. *Proc. Natl Acad. Sci. USA* 89, 10159–10163.
96. Fukumoto, S., Nishizawa, Y., Hosoi, M., Koyama, H., Yamakawa, K., Ohno, S. & Morii, H. (1997) Protein kinase C δ inhibits the proliferation of vascular smooth muscle cells by suppressing G_i cyclin expression. *J. Biol. Chem.* 272, 13816–13822.
97. Mischak, H., Goodnight, J., Kolch, W., Martiny-Baron, G., Schaeuble, C., Kazanietz, M.G., Blumberg, P.M., Pierce, J.H. & Mushinski, J.F. (1993) Overexpression of protein kinase C- δ and - ϵ in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. *J. Biol. Chem.* 268, 6090–6096.
98. Mishima, K., Ohno, S., Shitara, N., Yamaoka, K. & Suzuki, K. (1994) Opposite effects of the overexpression of protein kinase C γ and δ on the growth properties of human glioma cell line U251 MG. *Biochem. Biophys. Res. Commun.* 201, 363–372.
99. Harrington, E.O., Löffler, J., Nelson, P.R., Kent, K.C., Simons, M. & Ware, J.A. (1997) Enhancement of migration by protein kinase C α and inhibition of proliferation and cell cycle progression by protein kinase C δ in capillary endothelial cells. *J. Biol. Chem.* 272, 7390–7397.
100. Mischak, H., Pierce, J.H., Goodnight, J., Kazanietz, M.G., Blumberg, P.M. & Mushinski, J.F. (1993) Phorbol ester-induced myeloid differentiation is mediated by protein kinase C- α and - δ and not by protein kinase C- β , - ϵ , - ζ , and - η . *J. Biol. Chem.* 268, 20110–20115.
101. Li, W. & Pierce, J.H. (1996) Protein kinase C- δ , an important signaling molecule in the platelet-derived growth factor β receptor pathway. *Curr. Top. Microbiol. Immunol.* 211, 55–65.
102. Wang, Q.J., Acs, P., Goodnight, J., Giese, T., Blumberg, P.M., Mischak, H. & Mushinski, J.F. (1997) The catalytic domain of protein kinase C- δ in reciprocal δ and ϵ chimeras mediates phorbol ester-induced macrophage differentiation of mouse promyelocytes. *J. Biol. Chem.* 272, 76–82.
103. Lehel, C., Olah, Z., Mischak, H., Mushinski, J.F. & Anderson, W.B. (1994) Overexpressed protein kinase C- δ and - ϵ subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. *J. Biol. Chem.* 269, 4761–4766.
104. Saharinen, P., Ekman, N., Sarvas, K., Parker, P., Alitalo, K. & Silvennoinen, O. (1997) The Src tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase C δ . *Blood* 90, 4341–4353.
105. Tseng, C.-P., Kim, Y.-J., Kumar, R. & Verma, A.K. (1993) Involvement of protein kinase C in the transcriptional regulation of 12-O-tetradecanoylphorbol-13-acetate-inducible genes modulated by AP-1 or non-AP-1 transacting factors. *Carcinogenesis* 15, 707–711.
106. Hirai, S., Izumi, Y., Higa, K., Kaibuchi, K., Mizuno, K., Osada, S., Suzuki, K. & Ohno, S. (1994) Ras-dependent signal transduction is indispensable but not sufficient for the activation of AP1/Jun by PKC δ . *EMBO J.* 13, 2331–2340.
107. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K. & Ohno, S. (1996) Protein kinase C δ activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. *J. Biol. Chem.* 271, 23512–23519.
108. Ozawa, K., Yamada, K., Kazanietz, M.G., Blumberg, P.M. & Beaven, M.A. (1993) Different isoforms of protein kinase C mediate feedback inhibition of phospholipase C and stimulatory signals for exocytosis in rat RBL-2H3 cells. *J. Biol. Chem.* 268, 2280–2283.
109. Emoto, Y., Manome, Y., McInhardt, G., Kikawa, U., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W.W., Kamata, R., Weichselbaum, R. & Kufe, D. (1995) Proteolytic activation of protein kinase C δ by an ICE-like protease in apoptotic cells. *EMBO J.* 14, 6148–6156.
110. Emoto, Y., Kikawa, U., Manome, Y., Kharbanda, S. & Kufe, D. (1996) Activation of protein kinase C δ in human myeloid leukemia cells treated with 1- β -D-arabinofuranosylcytosine. *Blood* 87, 1990–1996.
111. Ghayur, T., Huganir, M., Talanian, R.V., Ratnowsky, S., Quinlan, C., Emoto, Y., Pandey, P., Datta, R., Huang, Y., Kharbanda, S., Allen, H., Kamen, R., Wong, W. & Kufe, D. (1996) Proteolytic activation of protein kinase C δ by an ICE/CED 3-like protease induces characteristics of apoptosis. *J. Exp. Med.* 184, 2399–2404.
112. Mizuno, M., Noda, K., Arai, T., Imayoshi, T., Kobayashi, Y., Akita, Y., Shimomura, M., Kishi, S. & Ohno, S. (1997) The proteolytic cleavage of protein kinase C isoforms, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. *Eur. J. Biochem.* 250, 7–18.
113. Sawai, H., Okazaki, T., Takeda, Y., Tashima, M., Sawada, H., Okuma, M., Kishi, S., Umehara, H. & Domae, N. (1997) Ceramide-induced translocation of protein kinase C- δ and - ϵ to the cytosol. *J. Biol. Chem.* 272, 2452–2458.

© FEBS 1999

564 M. Gschwendt (*Eur. J. Biochem.* 259)

114. Bhard, A., Kraeft, S.-K., Gounder, M., Pandey, P., Jin, S., Yuan, Z.-M., Lees-Miller, S.P., Welchelbaum, R., Weaver, D., Chen, L.B., Kufe, D. & Kharbanda, S. (1998) Inactivation of DNA-dependent protein kinase by protein kinase C δ : Implications for apoptosis. *Mol. Cell Biol.* 18, 6719–6728.
115. La Porta, C.A.M. & Comolli, R. (1995) Over-expression of protein kinase C δ is associated with a delay in preneoplastic lesion development in diethylnitrosamine-induced rat hepatocarcinogenesis. *Carcinogenesis* 16, 1233–1238.
116. Lu, Z., Hornia, A., Jiang, Y.-W., Zang, Q., Ohno, S. & Foster, D.A. (1997) Tumor promotion by depleting cells of protein kinase C δ . *Mol. Cell Biol.* 17, 3418–3428.
117. Gschwendt, M., Fürstenberger, G., Rose-John, S., Rogers, M., Kittstein, W., Petit, G.R., Herald, C.L. & Marks, F. (1988) Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA *in vivo* and *in vitro*. *Carcinogenesis* 9, 555–562.
118. Reddig, P.I., Dreckschmidt, N.E., Oberley, T.D. & Verma, A.K. (1998) Transgenic mice overexpressing protein kinase C δ in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA). *ASBMB Symposium on Protein Kinase C and Cellular Function*, Oct. 9–12, 1998, Abstract 78.
119. Kielbaso, K., Müller, H.-J., Meyer, H.E., Marks, F. & Gschwendt, M. (1995) Protein kinase C δ -specific phosphorylation of the elongation factor eEF-1 α and an eEF-1 α peptide at threonine 431. *J. Biol. Chem.* 270, 6156–6162.
120. Venema, R.C., Peters, H.I. & Traugh, J.A. (1991) Phosphorylation of elongation factor 1 (EF-1) and valyl-tRNA synthetase by protein kinase C and stimulation of EF-1 activity. *J. Biol. Chem.* 266, 12574–12580.
121. Venema, R.C., Peters, H.I. & Traugh, J.A. (1991) Phosphorylation of valyl-tRNA synthetase and elongation factor 1 in response to phorbol esters is associated with stimulation of both activities. *J. Biol. Chem.* 266, 11993–11998.
122. Germano, P., Gomez, J., Kazanietz, M.G., Blumberg, P.M. & Rivera, J. (1994) Phosphorylation of the γ chain of the high affinity receptor for immunoglobulin E by receptor-associated protein kinase C- δ . *J. Biol. Chem.* 269, 23102–23107.
123. Jideamu, N.M., Noland, T.A., Jr., Raynor, R.L., Blobe, G.C., Fabbro, D., Kazanietz, M.G., Blumberg, P.M., Hannun, Y.A. & Kuo, J.F. (1996) Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. *J. Biol. Chem.* 271, 23277–23283.
124. Maizels, E.T., Peters, C.A., Kline, M., Cutler, R.E., Jr. & Shammugam, M. & Hunzicker-Dunn, M. (1998) Heat-shock protein-25/27 phosphorylation by the δ isoform of protein kinase C. *Biochem. J.* 332, 703–712.
125. Mochly-Rosen, D. & Gordon, A.S. (1998) Anchoring proteins for protein kinase C: a means for isozyme selectivity. *FASEB J.* 12, 35–42.
126. Rosenberger, U., Shakibaei, M. & Buchner, K. (1995) Localization of non-conventional protein kinase C isoforms in bovine brain cell nuclei. *Biochem. J.* 305, 269–275.
127. Beckmann, R., Lindschau, C., Haller, H., Huch, F. & Buchner, K. (1994) Differential nuclear localization of protein kinase C isoforms in neuroblastoma X glioma hybrid cells. *Eur. J. Biochem.* 222, 335–343.
128. Keenan, C., Kelleher, D. & Long, A. (1995) Regulation of non-classical protein kinase C isoenzymes in a human T cell line. *Eur. J. Immunol.* 25, 13–17.
129. Knutson, K.L. & Hoenig, M. (1996) Regulation of distinct pools of protein kinase C δ in β cells. *J. Cell Biochem.* 60, 130–138.
130. Owen, P.J., Johnson, G.D. & Lord, J.M. (1996) Protein kinase C- δ associates with vimentin intermediate filaments in differentiated HL60 cells. *Exp. Cell Res.* 225, 366–373.
131. Barry, S.T. & Critchley, D.R. (1994) The RhoA-dependent assembly of focal adhesions in Swiss 3T3 cells is associated with increased tyrosine phosphorylation and the recruitment of both pp125PAK and protein kinase C- δ to focal adhesions. *J. Cell Sci.* 107, 2033–2045.
132. Liao, L., Hyatt, S.L., Chapple, C. & Jaked, S. (1994) Protein kinase C domains involved in interactions with other proteins. *Biochemistry* 33, 1229–1233.
133. Liao, L., Ramsay, K. & Jaked, S. (1994) Protein kinase C isozymes in progressively transformed rat embryo fibroblasts. *Cell Growth Diff.* 5, 1185–1194.
134. Johnson, J.A., Gray, M.O., Chen, C.-H. & Mochly-Rosen, D. (1996) A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. *J. Biol. Chem.* 271, 24962–24966.
135. Dekker, V.L. & Parker, P.J. (1997) Regulated binding of the protein kinase C substrate GAP-43 to the VQ/C2 region of protein kinase C- β . *J. Biol. Chem.* 272, 12747–12753.
136. Fujise, A., Mizuno, K., Ueda, Y., Osada, S., Hirai, S., Takayanagi, A., Shimizu, N., Owada, M.K., Nakajima, H. & Ohno, S. (1994) Specificity of the high affinity interaction of protein kinase C with a physiological substrate, myristoylated alanine-rich protein kinase C substrate. *J. Biol. Chem.* 269, 31642–31648.
137. Izumi, Y., Hirai, S., Tamai, Y., Fujisaki-Matsuoka, A., Nishimura, Y. & Ohno, S. (1997) A protein kinase C δ -binding protein SRBC whose expression is induced by serum starvation. *J. Biol. Chem.* 272, 7381–7389.
138. Bringer, S.L., Laner, R.W. & Duronio, V. (1996) Protein kinase C δ specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation. *J. Biol. Chem.* 271, 14514–14518.